PubRank

D J Rader

Author PubWeight™ 93.21‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Electron beam computed tomographic coronary calcium scanning: a review and guidelines for use in asymptomatic persons. Mayo Clin Proc 1999 3.32
2 Oestrogen and inhibition of oxidation of low-density lipoproteins in postmenopausal women. Lancet 1994 3.22
3 Regression of atherosclerosis induced by liver-directed gene transfer of apolipoprotein A-I in mice. Circulation 1999 2.84
4 A pilot study of ex vivo gene therapy for homozygous familial hypercholesterolaemia. Nat Med 1995 2.65
5 A novel endothelial-derived lipase that modulates HDL metabolism. Nat Genet 1999 2.56
6 Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice. J Clin Invest 1999 2.54
7 Absence of microsomal triglyceride transfer protein in individuals with abetalipoproteinemia. Science 1992 2.24
8 Cloning and gene defects in microsomal triglyceride transfer protein associated with abetalipoproteinaemia. Nature 1993 2.05
9 The adhesion receptor CD44 promotes atherosclerosis by mediating inflammatory cell recruitment and vascular cell activation. J Clin Invest 2001 2.04
10 Gene transfer and hepatic overexpression of the HDL receptor SR-BI reduces atherosclerosis in the cholesterol-fed LDL receptor-deficient mouse. Arterioscler Thromb Vasc Biol 2000 2.02
11 Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice. Nat Med 1998 1.98
12 The effects of total lymphocyte deficiency on the extent of atherosclerosis in apolipoprotein E-/- mice. J Clin Invest 1997 1.67
13 MDR and PRP: a comparison of methods for high-order genotype-phenotype associations. Hum Hered 2004 1.59
14 Absence of 12/15-lipoxygenase expression decreases lipid peroxidation and atherogenesis in apolipoprotein e-deficient mice. Circulation 2001 1.46
15 Overexpression of secretory phospholipase A(2) causes rapid catabolism and altered tissue uptake of high density lipoprotein cholesteryl ester and apolipoprotein A-I. J Biol Chem 2000 1.45
16 Deficiency in inducible nitric oxide synthase results in reduced atherosclerosis in apolipoprotein E-deficient mice. J Immunol 2000 1.43
17 Hepatic overexpression of microsomal triglyceride transfer protein (MTP) results in increased in vivo secretion of VLDL triglycerides and apolipoprotein B. J Lipid Res 1999 1.40
18 Plasma antigen levels of the lipoprotein-associated coagulation inhibitor in patient samples. Blood 1991 1.37
19 Mixed modelling to characterize genotype-phenotype associations. Stat Med 2005 1.31
20 Reduction of isoprostanes and regression of advanced atherosclerosis by apolipoprotein E. J Biol Chem 2001 1.23
21 Rapid regression of atherosclerosis induced by liver-directed gene transfer of ApoE in ApoE-deficient mice. Arterioscler Thromb Vasc Biol 1999 1.16
22 Inflammatory markers of coronary risk. N Engl J Med 2000 1.10
23 Safety and feasibility of liver-directed ex vivo gene therapy for homozygous familial hypercholesterolemia. Ann Surg 1996 1.06
24 Prolonged correction of hyperlipidemia in mice with familial hypercholesterolemia using an adeno-associated viral vector expressing very-low-density lipoprotein receptor. Mol Ther 2000 1.05
25 Hepatic apolipoprotein E expression promotes very low density lipoprotein-apolipoprotein B production in vivo in mice. J Lipid Res 2000 1.05
26 Delayed catabolism of high density lipoprotein apolipoproteins A-I and A-II in human cholesteryl ester transfer protein deficiency. J Clin Invest 1993 1.03
27 Cardiovascular risk assessment based on US cohort studies: findings from a National Heart, Lung, and Blood institute workshop. Circulation 2001 1.03
28 ABC1: connecting yellow tonsils, neuropathy, and very low HDL. J Clin Invest 1999 1.03
29 A 30-amino acid truncation of the microsomal triglyceride transfer protein large subunit disrupts its interaction with protein disulfide-isomerase and causes abetalipoproteinemia. J Biol Chem 1995 1.00
30 The effect of dehydroepiandrosterone supplementation to symptomatic perimenopausal women on serum endocrine profiles, lipid parameters, and health-related quality of life. J Clin Endocrinol Metab 1999 0.98
31 Evaluation of apoA-I kinetics in humans using simultaneous endogenous stable isotope and exogenous radiotracer methods. J Lipid Res 1993 0.96
32 Pharmacological management of high triglycerides and low high-density lipoprotein cholesterol. Curr Opin Pharmacol 2001 0.96
33 Expression of serum amyloid A protein in the absence of the acute phase response does not reduce HDL cholesterol or apoA-I levels in human apoA-I transgenic mice. J Lipid Res 1999 0.95
34 Hepatic expression of apolipoprotein E inhibits progression of atherosclerosis without reducing cholesterol levels in LDL receptor-deficient mice. Mol Ther 2000 0.95
35 Apolipoprotein(a) deposition in atherosclerotic plaques of cerebral vessels. A potential role for endothelial cells in lesion formation. Am J Pathol 1995 0.95
36 Association of traditional risk factors with coronary calcification in persons with a family history of premature coronary heart disease: the study of the inherited risk of coronary atherosclerosis. J Investig Med 2001 0.93
37 Liver-directed gene transfer and prolonged expression of three major human ApoE isoforms in ApoE-deficient mice. J Clin Invest 1997 0.93
38 Evidence that endothelial lipase remodels high density lipoproteins without mediating the dissociation of apolipoprotein A-I. J Lipid Res 2005 0.92
39 The alpha-defensins stimulate proteoglycan-dependent catabolism of low-density lipoprotein by vascular cells: a new class of inflammatory apolipoprotein and a possible contributor to atherogenesis. Blood 2000 0.91
40 Reduction in amyloid A amyloid formation in apolipoprotein-E-deficient mice. Am J Pathol 1998 0.89
41 State of the art: atherosclerosis in a limited edition. Nat Med 1998 0.88
42 Apolipoprotein A-II production rate is a major factor regulating the distribution of apolipoprotein A-I among HDL subclasses LpA-I and LpA-I:A-II in normolipidemic humans. Arterioscler Thromb Vasc Biol 1995 0.87
43 Correlation of apolipoprotein(a) isoproteins with Lp(a) density and distribution in fasting plasma. Atherosclerosis 1992 0.87
44 Psoriasis is associated with decreased plasma adiponectin levels independently of cardiometabolic risk factors. Clin Exp Dermatol 2014 0.87
45 Does exercise increase HDL cholesterol in those who need it the most? Arterioscler Thromb Vasc Biol 2001 0.86
46 Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia. Am J Cardiol 2001 0.85
47 Panstromal Schnyder's corneal dystrophy. Ultrastructural and histochemical studies. Ophthalmology 1992 0.85
48 The heart in Tangier disease. Severe coronary atherosclerosis with near absence of high-density lipoprotein cholesterol. Am J Clin Pathol 1992 0.85
49 Markedly increased secretion of VLDL triglycerides induced by gene transfer of apolipoprotein E isoforms in apoE-deficient mice. J Lipid Res 2000 0.85
50 Two different allelic mutations in the lecithin:cholesterol acyltransferase (LCAT) gene resulting in classic LCAT deficiency: LCAT (tyr83-->stop) and LCAT (tyr156-->asn). J Lipid Res 1993 0.85
51 Effects of coexpression of the LDL receptor and apoE on cholesterol metabolism and atherosclerosis in LDL receptor-deficient mice. J Lipid Res 2001 0.84
52 Metabolism of two forms of apolipoprotein B of VLDL by rat liver. J Lipid Res 1983 0.84
53 In vivo metabolism of apolipoproteins A-I and E in patients with abetalipoproteinemia: implications for the roles of apolipoproteins B and E in HDL metabolism. J Lipid Res 1994 0.83
54 Defensin stimulates the binding of lipoprotein (a) to human vascular endothelial and smooth muscle cells. Blood 1997 0.83
55 Lipoprotein(a). Clinical approach to a unique atherogenic lipoprotein. JAMA 1992 0.83
56 Genetic polymorphism of human plasma apolipoprotein A-IV is due to nucleotide substitutions in the apolipoprotein A-IV gene. J Biol Chem 1990 0.81
57 Phenotypic correction of lipid storage and growth arrest in wolman disease fibroblasts by gene transfer of lysosomal acid lipase. Hum Gene Ther 2001 0.81
58 In vivo metabolism of apolipoprotein A-I in a patient with homozygous familial hypercholesterolemia. Arterioscler Thromb 1992 0.81
59 Lipoproteins containing apolipoprotein B isolated from patients with abetalipoproteinemia and homozygous hypobetalipoproteinemia: identification and characterization. Atherosclerosis 1995 0.81
60 Effect of antioxidant vitamins on low density lipoprotein oxidation and impaired endothelium-dependent vasodilation in patients with hypercholesterolemia. J Am Coll Cardiol 1994 0.81
61 Increased catabolic rate of low density lipoproteins in humans with cholesteryl ester transfer protein deficiency. J Clin Invest 1995 0.81
62 Antioxidant therapy and atherosclerosis: animal and human studies. Trends Cardiovasc Med 2001 0.80
63 Does nicotinic acid (niacin) lower blood pressure? Int J Clin Pract 2008 0.80
64 Heterozygosity for apolipoprotein E-4Philadelphia(Glu13----Lys, Arg145----Cys) is associated with incomplete dominance of type III hyperlipoproteinemia. J Biol Chem 1992 0.80
65 ApoA-II kinetics in humans using endogenous labeling with stable isotopes: slower turnover of apoA-II compared with the exogenous radiotracer method. J Lipid Res 1996 0.79
66 A new feature on the cholesterol-lowering landscape. Nat Med 2001 0.78
67 Counter-current chromatography of lipoproteins with a polymer phase system using the cross-axis synchronous coil planet centrifuge. J Chromatogr 1992 0.78
68 High-density lipoprotein metabolism: molecular targets for new therapies for atherosclerosis. Curr Atheroscler Rep 2000 0.78
69 [Laboratory assessment of HDL heterogeneity and function]. Ann Biol Clin (Paris) 2009 0.78
70 Statins and cerebrovascular disease: plaque attack to prevent brain attack. Vasc Med 1999 0.78
71 HDL: structure, function and metabolism. Prog Lipid Res 1991 0.77
72 In vivo protein metabolism utilizing stable isotopes and mass spectrometry: a new approach to the study of mutant proteins in humans. Trans Assoc Am Physicians 1990 0.77
73 Three genetic variants of human plasma apolipoprotein A-IV. apoA-IV-1(Thr347----Ser), apoA-IV-0(Lys167----Glu,Gln360----His), and apoA-IV-3(Glu165----Lys). J Biol Chem 1991 0.76
74 Comparison of human apoA-I expression in mouse models of atherosclerosis after gene transfer using a second generation adenovirus. J Lipid Res 1997 0.76
75 Human plasma apolipoproteins A-IV-0 and A-IV-3. Molecular basis for two rare variants of apolipoprotein A-IV-1. J Biol Chem 1990 0.76
76 Decreased plasma levels of lipoprotein(a) in patients with hypertriglyceridemia. Atherosclerosis 1994 0.76
77 Slaying the metabolic syndrome. Are we battling the Hydra or the Chimera? Minerva Endocrinol 2004 0.76
78 Angioid streaks associated with abetalipoproteinemia. Ophthalmic Genet 1995 0.76
79 Lipoprotein (a) in patients with hyperlipidaemia. Eur J Clin Invest 1995 0.75
80 Genetic susceptibility to atherosclerosis: insights from mice. Circ Res 2000 0.75
81 Gene therapy for genetic lipid disorders: lipoprotein lipase deficiency as a paradigm. Neth J Med 2005 0.75
82 Cholesterol and all-cause mortality in Honolulu. Lancet 2001 0.75
83 Management of lipid disorders. Rheum Dis Clin North Am 1999 0.75
84 Lipoproteins and the endothelium: insights from clinical research. Semin Thromb Hemost 2000 0.75
85 A comparison of Lp(a) levels in fresh and frozen plasma using ELISAs with either anti-apo(a) or anti-apoB reporting antibodies. Chem Phys Lipids 1994 0.75
86 Berman's simulation analysis and modeling. Adv Exp Med Biol 1991 0.75
87 Lipoprotein(a) levels and heart transplantation atherosclerosis. Am Heart J 1998 0.75
88 Recent advances in lipoprotein metabolism and the genetic dyslipoproteinemias. Adv Exp Med Biol 1991 0.75
89 Nanoparticle Knudsen layers in gas-filled microscale geometries. Phys Rev E Stat Nonlin Soft Matter Phys 2008 0.75
90 Molecular gas dynamics observations of Chapman-Enskog behavior and departures there from in nonequilibrium gases. Phys Rev E Stat Nonlin Soft Matter Phys 2004 0.75
91 Changes in lipoprotein(a) concentration after orthotopic heart transplantation. Am Heart J 2000 0.75